A retrospective study on efficacy of the ERAS protocol in patients undergoing surgery for Crohn disease: A propensity score analysis.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
06 2020
Historique:
received: 11 09 2019
revised: 13 01 2020
accepted: 15 01 2020
pubmed: 23 2 2020
medline: 20 7 2021
entrez: 23 2 2020
Statut: ppublish

Résumé

Enhanced Recovery After Surgery (ERAS) offers many benefits for patients with colorectal cancer. However, its application to patients with Crohn's disease (CD) is questioned. The aim of this propensity-matched study was to validate the results of ERAS protocol on CD patients. Patients undergoing ileocolic resection for primary or relapsed CD from 2007 to 2018 were retrospectively analyzed and propensity-matched into two equal groups (ERAS vs standard of care). Demographic characteristics, length of stay, bowel function, oral intake, and perioperative morbidity were analyzed. Ninety four out of 299 patients were selected for analysis. No significant difference was observed for age, gender, American Society of Anesthesiologists score, body mass index, previous surgery and therapy, operative time and laparoscopy. The median length of stay in ERAS and non-ERAS groups was 6 and 8 days (p < 0.001). Median postoperative days of first bowel movement and solid oral intake were day 1 and day 2 p < 0,001, and day 2 and day 4.5 p < 0,001 in ERAS and non-ERAS group, respectively. No statistically differences in other postoperative outcomes were shown. ERAS implementation showed decreased length of stay, faster bowel function restoration and earlier solid oral intake in patients who underwent laparoscopic or open ileocolic resection for primary or relapsing CD.

Sections du résumé

BACKGROUND
Enhanced Recovery After Surgery (ERAS) offers many benefits for patients with colorectal cancer. However, its application to patients with Crohn's disease (CD) is questioned.
AIM
The aim of this propensity-matched study was to validate the results of ERAS protocol on CD patients.
METHODS
Patients undergoing ileocolic resection for primary or relapsed CD from 2007 to 2018 were retrospectively analyzed and propensity-matched into two equal groups (ERAS vs standard of care). Demographic characteristics, length of stay, bowel function, oral intake, and perioperative morbidity were analyzed.
RESULTS
Ninety four out of 299 patients were selected for analysis. No significant difference was observed for age, gender, American Society of Anesthesiologists score, body mass index, previous surgery and therapy, operative time and laparoscopy. The median length of stay in ERAS and non-ERAS groups was 6 and 8 days (p < 0.001). Median postoperative days of first bowel movement and solid oral intake were day 1 and day 2 p < 0,001, and day 2 and day 4.5 p < 0,001 in ERAS and non-ERAS group, respectively. No statistically differences in other postoperative outcomes were shown.
CONCLUSIONS
ERAS implementation showed decreased length of stay, faster bowel function restoration and earlier solid oral intake in patients who underwent laparoscopic or open ileocolic resection for primary or relapsing CD.

Identifiants

pubmed: 32085992
pii: S1590-8658(20)30032-3
doi: 10.1016/j.dld.2020.01.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-629

Informations de copyright

Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Auteurs

Michela Mineccia (M)

Department of Chirurgia Generale e Oncologica, Ospedale Mauriziano Umberto I, Torino, Italy. Electronic address: mmineccia@mauriziano.it.

Francesca Menonna (F)

Department of Chirurgia Generale e Oncologica, Ospedale Mauriziano Umberto I, Torino, Italy.

Paola Germani (P)

Department of Chirurgia Generale e Oncologica, Ospedale Mauriziano Umberto I, Torino, Italy.

Valentina Gentile (V)

Department of Chirurgia Generale e Oncologica, Ospedale Mauriziano Umberto I, Torino, Italy.

Paolo Massucco (P)

Department of Chirurgia Generale e Oncologica, Ospedale Mauriziano Umberto I, Torino, Italy.

Rodolfo Rocca (R)

Department of Gastroenterology, Ospedale Mauriziano Umberto I, Torino, Italy.

Alessandro Ferrero (A)

Department of Chirurgia Generale e Oncologica, Ospedale Mauriziano Umberto I, Torino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH